“…a tumor in case of 18 F-FDG that consumes more glucose than a healthy tissue. 53 Using IONP, it was possible to bring several improvement to the standard PET/SPECT imaging method by: (i) binding different radio-tracers to IONP [18F]uorodeoxyglucose (FDG), copper-61/64, gallium-66/68, zirconium-89, and iodine-124 for PET, 54 and 99mTc, 125I, 111I, 125I and 131I for SPECT, [54][55][56] that increase radio-tracer lifetime and targeting efficacy, 55 (ii) enabling simultaneous anatomical and functional imaging by combining PET/SPEC with MRI, taking advantage of the MRI contrasting ability of IONP, (iii) enlarging the SPECT/ PET imaging capacity to a therapeutic activity through the use of a theranostic IONP probe that can trigger drugs delivery, immunotherapy, hyperthermia, or photodynamic therapy. 19,57 In addition, PET/SPECT lead to high detection sensitivity, e.g.…”